In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Poll|Articles|February 14, 2024
POLL: Are You Attending Masterclasses in Dermatology?
Author(s)Emma Andrus, Associate Editor
Click here to answer our poll about the upcoming conference in Puerto Rico.
Advertisement
Are you attending Masterclasses in Dermatology?
This President's Day weekend,
The conference will feature updates in dermatology, as well as related disciplines, including rheumatology, infectious disease, inflammatory disease, and gastroenterology.
Dermatology Times recently spoke with course directors Alice Gottlieb, MD, PhD, of Mount Sinai in New York, New York; Joseph Merola, MD, MMSc, of UT Southwestern Medical Center in Dallas, Texas; and Daniel Siegel, MD, of SUNY Downstate Health Sciences University in Brooklyn, New York, to preview the upcoming conference.
Read their insights
Unable to make it to Puerto Rico? Masterclasses in Dermatology also offers a virtual registration option. Interested individuals can access on-demand sessions available 5 days after the conclusion of the meeting.
Answered "yes" to this poll? Tell us more about what sessions you are most looking forward to by emailing
Advertisement
Related to this article
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Advertisement
Advertisement
Trending on Dermatology Times
1
Hidradenitis Suppurativa Claims Data: Sex Parity and Rural Care Gaps
2
Regenerative Approaches in Skin and Hair Care and Hair Loss Research
3
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
4
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
5